Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Articles published by Tempus AI, Inc.
< Previous
1
2
3
Next >
Tempus and Medtronic Announce ALERT Trial Results Showing AI-Driven EHR Notifications Improve Treatment for Significant Valvular Heart Disease
April 01, 2026
From
Tempus AI, Inc.
Via
Business Wire
Tickers
TEM
Tempus Announces Strategic Collaboration with Daiichi Sankyo to Advance AI-Driven Biomarker Discovery and Clinical Differentiation Across an ADC Clinical Program
March 25, 2026
From
Tempus AI, Inc.
Via
Business Wire
Tempus and Blood Cancer United® Announce Collaboration to Develop One Of the Largest Pediatric Acute Myeloid Leukemia Real-World Data Registries
March 17, 2026
From
Tempus AI, Inc.
Via
Business Wire
Tickers
TEM
Tempus Announces Study Highlighting the Role of Advanced Genomic Profiling Features in Identifying Clinically Actionable Findings
March 11, 2026
From
Tempus AI, Inc.
Via
Business Wire
Tickers
TEM
Tempus Announces Strategic Collaboration Agreement with Merck to Accelerate AI-Driven Precision Medicine
March 03, 2026
From
Tempus AI, Inc.
Via
Business Wire
Tickers
TEM
Tempus to Participate in the Morgan Stanley Technology, Media & Telecom Conference
February 26, 2026
From
Tempus AI, Inc.
Via
Business Wire
Tickers
TEM
Tempus Reports Fourth Quarter and Full Year 2025 Results
February 24, 2026
From
Tempus AI, Inc.
Via
Business Wire
Tickers
TEM
Tempus Announces Novel Pan-Cancer HRD-RNA Algorithm
February 18, 2026
From
Tempus AI, Inc.
Via
Business Wire
Tickers
TEM
Tempus Announces Collaboration with Median Technologies to Integrate AI-Powered Lung Cancer Screening into the Pixel Platform
February 12, 2026
From
Tempus AI, Inc.
Via
Business Wire
Tickers
TEM
Tempus to Report Fourth Quarter and Full Year 2025 Financial Results on February 24
February 10, 2026
From
Tempus AI, Inc.
Via
Business Wire
Tickers
TEM
Tempus Reveals Its AI-Driven IPS Test More Accurately Predicts Immunotherapy Benefit Compared to Conventional Biomarkers
January 27, 2026
From
Tempus AI, Inc.
Via
Business Wire
Tickers
TEM
Tempus Announces the Launch of Paige Predict
January 21, 2026
From
Tempus AI, Inc.
Via
Business Wire
Tickers
TEM
Northwestern Medicine Selects Tempus to Expand Genomic Testing
January 12, 2026
From
Tempus AI, Inc.
Via
Business Wire
Tickers
TEM
Tempus Achieves Record Total Contract Value Exceeding $1.1 Billion
January 11, 2026
From
Tempus AI, Inc.
Via
Business Wire
Tickers
TEM
Tempus Announces Preliminary Fourth Quarter and Full Year 2025 Results
January 11, 2026
From
Tempus AI, Inc.
Via
Business Wire
Tickers
TEM
Tempus Announces Eight Abstracts Accepted for Presentation at the 2026 ASCO® Gastrointestinal Cancers Symposium
January 08, 2026
From
Tempus AI, Inc.
Via
Business Wire
Tickers
TEM
Tempus to Present at 44th Annual J.P. Morgan Healthcare Conference
January 06, 2026
From
Tempus AI, Inc.
Via
Business Wire
Tickers
TEM
Tempus Announces Ten Abstracts Accepted for Presentation at the 2025 San Antonio Breast Cancer Symposium
December 09, 2025
From
Tempus AI, Inc.
Via
Business Wire
Tickers
TEM
Tempus to Participate in the Piper Sandler 37th Annual Healthcare Conference
November 18, 2025
From
Tempus AI, Inc.
Via
Business Wire
Tickers
TEM
Tempus and IFLI Announce Study to Advance Follicular Lymphoma Research
November 14, 2025
From
Tempus AI, Inc.
Via
Business Wire
Tickers
TEM
Tempus Announces Six Abstracts Accepted for Presentation at the Society for Immunotherapy of Cancer Annual Meeting 2025
November 05, 2025
From
Tempus AI, Inc.
Via
Business Wire
Tickers
TEM
Tempus Reports Third Quarter 2025 Results
November 04, 2025
From
Tempus AI, Inc.
Via
Business Wire
Tickers
TEM
Tempus to Participate in the Stifel 2025 Healthcare Conference
October 28, 2025
From
Tempus AI, Inc.
Via
Business Wire
Tickers
TEM
Tempus to Report Third Quarter 2025 Financial Results on November 4
October 21, 2025
From
Tempus AI, Inc.
Via
Business Wire
Tickers
TEM
Tempus Announces Collaboration with Whitehawk Therapeutics to Advance Biomarker-Driven Oncology Research
October 16, 2025
From
Tempus AI, Inc.
Via
Business Wire
Tickers
TEM
Tempus Announces Six Abstracts Accepted for Presentation at the European Society for Medical Oncology Congress 2025
October 15, 2025
From
Tempus AI, Inc.
Via
Business Wire
Tickers
TEM
Tempus Selected by ARPA-H to Provide CRO and Testing Services for the ADAPT Program, Advancing Precision Cancer Therapy
October 09, 2025
From
Tempus AI, Inc.
Via
Business Wire
Tickers
TEM
Tempus Receives U.S. FDA 510(k) Clearance for Tempus xR IVD, its RNA NGS In Vitro Diagnostic Device
September 22, 2025
From
Tempus AI, Inc.
Via
Business Wire
Tickers
TEM
Tempus Receives U.S. FDA Special 510(k) Clearance for Updated Tempus Pixel Device
September 11, 2025
From
Tempus AI, Inc.
Via
Business Wire
Tickers
TEM
Tempus Announces New Study in JCO Precision Oncology Validating PurIST® Algorithm for Enhanced Therapy Selection in Pancreatic Cancer
September 09, 2025
From
Tempus AI, Inc.
Via
Business Wire
Tickers
TEM
< Previous
1
2
3
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
